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Adrenomedullin (AM) is a 52 amino acid peptide that has shown predominant anti-inflammatory activities. In the present study,
we evaluated the possible therapeutic eﬀect of this peptide in an experimental model of acute inflammation, the carrageenan-
(CAR-) induced pleurisy. Pleurisy was induced by injection of CAR into the pleural cavity of mice. AM (200 ng/kg) was
administered by intraperitoneal route 1 h after CAR, and the animals were sacrificed 4 h after that. AM treatment attenuated
the recruitment of leucocytes in the lung tissue and the generation and/or the expression of the proinflammatory cytokines as
well as the expression of the intercellular cell adhesion molecules. Moreover, AM inhibited the induction of inducible nitric
oxide synthase (iNOS), thereby abating the generation of nitric oxide (NO) and prevented the oxidative and nitroxidative lung
tissue injury, as shown by the reduction of nitrotyrosine, malondialdehyde (MDA), and poly (ADP-ribose) polymerase (PARP)
levels. Finally, we demonstrated that these anti-inflammatory eﬀects of AM were associated with the inhibition of nuclear factor-
κB (NF-κB) activation. All these parameters were markedly increased by intrapleural CAR in the absence of any treatment. We
report that treatment with AM significantly reduces the development of acute lung injury by downregulating a broad spectrum of
inflammatory factors.
1. Introduction
Injection of carrageenan (CAR) into the pleural space leads
to local inflammation, infiltration by polymorphonuclear
leukocytes (PMN), and lung injury [1]. This experimental
model of pleurisy has been widely used to investigate the
pathophysiology of acute inflammation and also to evaluate
the eﬃcacy of drugs in inflammation. In particular, the initial
phase of acute inflammation. The acute reaction elicited by
intrapleural injection of CAR is characterized by a marked
accumulation of pleural exudate, measured by protein
concentration, and intense migration of polymorphonuclear
leukocytes (PMNs) into the pleural cavity [1]. PMNsmoving
out of the circulation into the inflamed tissue have a key
function in the breakdown and remodeling of injured tissue
[2]. In addition, oxidative stress is one of the earliest and
most important components of acute lung injury induced by
CAR and it is characterized by high levels of reactive oxygen
species (ROS) and reactive nitrogen species (RNS). These
molecules may lead to cell death by oxidative damage to
DNA and proteins, lipid peroxidation in the cell membranes,
and neutrophil recruitment on the injury tissue [3]. Fur-
thermore, in the lungs, many noxious/inflammatory stimuli
have been shown to activate transcription of nuclear factor
κB (NF-κB), implicating this pathway as a focal point for
induction of lung inflammation [4]. In normal conditions,
NF-κB, which is mainly composed of the subunits p50 and
p65, is found in the cytoplasm of cells as inactive form bound
to its inhibitor IκB. After an inflammatory stimulus, IκB
kinases (IKK) phosphorylates IκB, which will be degraded
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releasing NF-κB that will be translocated to the nucleus to
induce transcription of genes involved in the early onset of
the inflammatory response [5].
Adrenomedullin (AM) is a 52-amino acid polypeptide
initially isolated from human pheochromocytoma by Kita-
mura et al. [6]. AM is synthesized and secreted from a
variety of tissues and organs, including adrenal medulla,
lung, kidney, spleen, and heart. Accumulating evidence
reveals the multifunctional biological activities of this pep-
tide, which include vasorelaxation, bronchodilation, diuretic
action, inhibition of aldosterone secretion, neurotransmis-
sion, antimicrobial activity, or growth regulation [7]. This
peptide is found in low picomolar concentrations in the cir-
culation and is reported to enhance in a coordinated fashion
in experimental and clinical conditions of inflammation and
sepsis [8].
Moreover, AM expression has shown to be increased
in animals and humans with acute lung injury [9–11]. In
the lungs, AM is expressed in many cell types, including
bronchial epithelium, bronchial smoothmuscles, pulmonary
vasculature, and macrophages [12]. Plasma AM level is
increased in a number of diseases, including essential
hypertension, acute myocardial infarction, congestive heart
failure, and renal failure [13, 14].
Recently Ceyhan et al. have measured the plasma levels
of AM in asthma and in chronic obstructive airway disease
and found that they were raised [15]. Plasma AM is markedly
increased in endotoxic shock, suggesting that AM may be
secreted in response to endotoxic shock [16] in sepsis [17],
rheumatoid arthritis [18], and inflammatory bowel diseases
[19]. Furthermore, anti-inflammatory eﬀects of this peptide
have been previously demonstrated in various models of
lung disease. Along these lines, Itoh et al. [11] showed that
AM infusion ameliorated LPS-induced acute lung injury
in rats. In the same way, administration of AM after gut
ischemia-reperfusion prevented acute lung injury through
downregulation of proinflammatory cytokines [20]. Given
that AM has emerged as a potential anti-inflammatory
agent, the present study was designed to explore its possible
therapeutic eﬀect in an experimental model of CAR-induced
pleurisy as well as to examine the underlying mechanisms
responsible for its eﬀects on this model of acute lung injury.
2. Material and Methods
2.1. Animals. Male CD mice (weight 20–25 g; Harlan Nos-
san, Milan, Italy) were used in these studies. The animals
were housed in a controlled environment and provided
with standard rodent chow and water. Animal care was in
compliance with Italian regulations on the protection of
animals used for experimental and other scientific purposes
(D.M. 116192) as well as with EEC regulations (O.J. of E.C.
L358/1 12/18/1986).
2.2. Carrageenan-Induced Pleurisy. Pleurisy by CAR was
induced as previously described [21]. Mice were anaes-
thetized with isoflurane and subjected to a skin incision at
the level of the left sixth intercostals space. The underlying
muscle was dissected and saline (0.1mL) or saline containing
2% λ-CAR (0.1mL) was injected into the pleural cavity.
The skin incision was closed with a suture and the animals
were allowed to recover. At 4 h after the injection of
CAR, the animals were killed by inhalation of CO2. The
chest was carefully opened and the pleural cavity rinsed
with 1mL of saline solution containing heparin (5UmL−1)
and indomethacin (10 μgmL−1). The exudates and washing
solution were removed by aspiration. Any exudates which
were contaminated with blood were discarded.
2.3. Experimental Design. Mice were randomly allocated into
the following groups:
(i) CAR + saline group—mice were subjected to CAR-
induced pleurisy (N = 10);
(ii) CAR + AM group—same as the CAR + saline group
but AM (200 ng/kg, i.p.) was administered 1 h after
CAR (N = 10);
(iii) Sham + saline group—sham-operated group in which
identical surgical procedures to the CAR group was
performed, except that the saline was administered
instead of CAR (N = 10);
(iv) Sham + AM group—same as the sham + saline group
but AM (200 ng/kg, i.p.) was administered 1 h after
saline solution (N = 10).
The dose of AM used (200 ng/kg, i.p.) was based on
previous in vivo studies [19].
In a separate set of experiments, AM was administered
in diﬀerent doses in order to examine the dose-dependent
therapeutic eﬀect of adrenomedullin in a model of CAR-
induced acute lung injury. Were used for this purpose the
following groups:
(i) CAR + saline group—mice were subjected to CAR-
induced pleurisy (N = 10);
(ii) CAR + AM group—same as the CAR + saline group
but AM (100 ng/kg, i.p.) was administered 1 h after
CAR (N = 10);
(iii) CAR + AM group—same as the CAR + saline group
but AM (50 ng/kg, i.p.) was administered 1 h after
CAR (N = 10);
(iv) Sham + saline group—sham-operated group in which
identical surgical procedures to the CAR group was
performed, except that the saline was administered
instead of CAR (N = 10);
(v) Sham + AM group—same as the sham + saline group
but AM (100 ng/kg, i.p.) was administered 1 h after
saline solution (N = 10);
(vi) Sham + AM group—same as the sham + saline group
but AM (50 ng/kg, i.p.) was administered 1 h after
saline solution (N = 10).
2.4. Histological Examination. Lung tissues samples were
taken 4 h after injection of CAR. Lung tissue samples were
fixed for 1 week in 10% (w/v) PBS-buﬀered formaldehyde
Mediators of Inflammation 3
solution at room temperature, dehydrated using graded
ethanol and embedded in Paraplast (Sherwood Medical,
Mahwah, NJ, USA). Sections were then deparaﬃnized with
xylene, stained with hematoxylin and eosin. All sections were
studied using Axiovision Zeiss (Milan, Italy) microscope.
The following morphological criteria were used for scoring:
0, normal lung; grade 1, minimal oedema or infiltration
of alveolar or bronchiolar walls; grade 3, moderate oedema
and inflammatory cell infiltration without obvious damage
to lung architecture; grade 4, severe inflammatory cell
infiltration with obvious damage to lung architecture. All the
histological studies were performed in a blinded fashion.
2.5. Measurement of Cytokines. IL-10, TNF-α, and IL-1β
levels were evaluated in the exudates 4 h after the induction
of pleurisy by CAR injection as previously described [22].
The assay was carried out using a colorimetric commercial
ELISA kit (Calbiochem-Novabiochem Corporation, Milan,
Italy). The ELISA has a lower detection limit of 5 pg/mL.
2.6. Measurement of Nitrite-Nitrate Concentration. Total
nitrite in exudates, an indicator of NO synthesis, was mea-
sured as previously described [23]. Briefly, the nitrate in
the sample was first reduced to nitrite by incubation with
nitrate reductase (670mU/mL) and β-nicotinamide adenine
dinucleotide 3′-phosphate (NADPH) (160 μM), at room
temperature for 3 h. The total nitrite concentration in
the samples was then measured using the Griess reaction,
by adding 100 μL of Griess reagent (0.1%w/v) naphthyl-
ethylen-diamide-dihydrochloride in H2O and 1% (w/v)
sulphanilamide in 5% (v/v) concentrated H3PO4; vol. 1 : 1)
to the 100 μl sample. The optical density at 550 nm (OD550)
was measured using ELISA microplate reader (SLT-Lab
Instruments, Salzburg, Austria). Nitrite concentrations were
calculated by comparison with OD550 of standard solu-
tions of sodium nitrite prepared in H2O and expressed as
nmol/mL.
2.7. Immunohistochemical Localization of Intercellular Cell
AdhesionMolecule (ICAM-1) P-Selectin, iNOS, IL-1β, TNF-α,
Nitrotyrosine, and Poly (ADP-Ribose) Polymerase (PARP). At
the end of the experiment, the tissues were fixed in 10% (w/v)
PBS-buﬀered formaldehyde and 8 μm sections were prepared
from paraﬃn-embedded tissues. After deparaﬃnization,
endogenous peroxidase was quenched with 0.3% (v/v)
hydrogen peroxide in 60% (v/v) methanol for 30min. The
sections were permeabilized with 0.1% (w/v) Triton X-100
in PBS for 20min. Nonspecific adsorption was minimized by
incubating the section in 2% (v/v) normal goat serum in PBS
for 20min. Endogenous biotin or avidin binding sites were
blocked by sequential incubation for 15min with both labels
respectively. Sections were incubated overnight with anti-
iNOS (1 : 500, Transduction Laboratories in PBS, v/v), anti-
nitrotyrosine rabbit polyclonal antibody (Upstate, 1 : 500 in
PBS, v/v), anti-PARP antibody (BioMol, 1 : 200 in PBS, v/v),
anti-TNF-α ligand antibody (Santa Cruz Biotechnology,
1 : 500 in PBS, v/v), anti-IL-1β ligand antibody (Santa Cruz
Biotechnology, 1 : 500 in PBS, v/v), anti-ICAM-1 antibody
(Santa Cruz Biotechnology, 1 : 500 in PBS, v/v), or with anti-
P-selectin polyclonal antibody (Santa Cruz Biotechnology,
1 : 500 in PBS, v/v). Sections were washed with PBS and
incubated with secondary antibody. Specific labeling was
detected with a biotin-conjugated goat anti-rabbit IgG
and avidin-biotin peroxidase complex (Vector Laboratories,
DBA). In order to confirm that the immunoreaction for the
nitrotyrosine was specific, some sections were also incubated
with the primary antibody (anti-nitrotyrosine) in the pres-
ence of excess nitrotyrosine (10mM) to verify the binding
specificity. To verify the binding specificity for iNOS, IL-1β,
TNF-α, PARP, ICAM-1, P-selectin, some sections were also
incubated with only the primary antibody (no secondary)
or with only the secondary antibody (no primary). In these
situations no positive staining was found in the sections
indicating that the immunoreaction was positive in all the
experiments carried out.
2.8. Myeloperoxidase (MPO) Activity. MPO activity, an
indicator of PMN accumulation, was determined as pre-
viously described [24]. At the specified time following in-
jection of CAR, lung tissues were obtained and weighed,
each piece homogenized in a solution containing 0.5%
(w/v) hexadecyltrimethyl-ammonium bromide dissolved in
10mM potassium phosphate buﬀer (pH 7) and centrifuged
for 30min at 20,000×g at 4◦C. An aliquot of the supernatant
was then allowed to react with a solution of tetramethylben-
zidine (1.6mM) and 0.1mM hydrogen peroxide. The rate of
change in absorbance was measured spectrophotometrically
at 650 nm. MPO activity was defined as the quantity of
enzyme degrading 1 μmol of peroxide min−1 at 37◦C and was
expressed in units per 100mg of wet tissue.
2.9. Malondialdehyde (MDA) Measurement. MDA levels in
the lung tissue were determined as an indicator of lipid per-
oxidation as previously described [25]. Lung tissue collected
at the specified time, was homogenized in 1.15% (w/v) KCl
solution. A 100 μL aliquot of the homogenate was added to
a reaction mixture containing 200 μL of 8.1% (w/v) SDS,
1.5mL of 20% (v/v) acetic acid (pH 3.5), 1.5mL of 0.8%
(w/v) thiobarbituric acid and 700 μL distilled water. Samples
were then boiled for 1 h at 95◦C and centrifuged at 3,000×g
for 10min. The absorbance of the supernatant was measured
using spectrophotometry at 650 nm. Results were expressed
as μM/100mg wet tissue.
2.10. Western Blot Analysis for ICAM, P-Selectin, iNOS, IκB-
α, NF-κB p65, IKK-α, PKA, and Phospho-NF-κB (Ser536).
Cytosolic and nuclear extracts were prepared with slight
modifications. Briefly, lung tissues from each mouse were
suspended in extraction Buﬀer A containing 10mM Hepes,
10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT,
0.5mM PMSF, 3 μg/mL pepstatin A, 2 μg/mL leupeptin,
15 μg/mL Trypsin inhibitor, 40 μM Benzamidine, homoge-
nized at the highest setting for 2min, and centrifuged at
13,000×g for 3min at 4◦C. Supernatants represented the
cytosolic fraction. The pellets, containing enriched nuclei,
were resuspended in Buﬀer B containing 20mM Hepes,
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1.5mM MgCl2, 0.4M NaCl, 1mM EGTA, 1mM EDTA,
1mM DTT, 0.5mM PMSF, 3 μg/mL pepstatin A, 2 μg/mL
leupeptin, 15 μg/mL Trypsin inhibitor, 40 μM Benzamidine,
1% NONIDET P40, 20% Glycerol. After centrifugation
10min a 13,000×g at 4◦C, the supernatants containing
the nuclear protein were stored at −80◦C for further anal-
ysis. The levels of ICAM, P-selectin, IκB-α, iNOS, IKK-
α, PKA, and phospho-NF-κB (ser536) were quantified in
cytosolic fraction from lung tissue collected 4 h after CAR
administration, while NF-κB p65 levels were quantified in
nuclear fraction. Protein concentration in cell lysates was
determined by Bio-Rad Protein Assay (BioRad, Richmond
CA, USA) and 50 μg of cytosol and nuclear extract from
each sample was analyzed. Proteins were separated by a
12% SDS-polyacrylamide gel electrophoresis and transferred
on PVDF membrane (Hybond-P, Amershan Biosciences,
UK). The membrane was blocked with 0.1% TBS-Tween
containing 5% nonfat milk for 1 h at room temperature
and subsequently probed with specific Abs ICAM (Santa
Cruz Biotechnology, 1 : 500), P-selectin (Santa Cruz Biotech-
nology, 1 : 500), IκB-α (Santa Cruz Biotechnology, 1 : 1000),
or anti-iNOS (1 : 1000; Transduction) or anti-NF-κB p65
(1 : 1000; Santa Cruz Biotechnology) IKK-α (Santa Cruz
Biotechnology, 1 : 1000), PKA (Santa Cruz Biotechnology,
1 : 1000) and phospho-NF-κB (ser536) (Santa Cruz Biotech-
nology, 1 : 1000) in 1x PBS, 5% w/v nonfat dried milk,
0.1% Tween-20 (PMT) at 4◦C, overnight. Membranes were
incubated with peroxidase-conjugated bovine anti-mouse
IgG secondary antibody or peroxidase-conjugated goat anti-
rabbit IgG (1 : 2000, Jackson ImmunoResearch, West Grove,
PA, USA) for 1 h at room temperature. To ascertain that
blots were loaded with equal amounts of proteic lysates, they
were also incubated in the presence of the antibody against
β-actin protein (1 : 10,000 Sigma-Aldrich Corp.) and anti-
lamin B1 (1 : 10,000 Sigma-Aldrich Corp.). Protein bands
were detected with Super-Signal West Pico Chemilumines-
cent (PIERCE). The relative quantification of the protein
bands of ICAM(∼110 kDa), P-selectin(∼140 kDa), IκB-α (∼
37 kDa), NF-κB p65 (∼65 kDa), iNOS (∼130 kDa), IKK-α
(∼85 kDa), PKA (∼40 kDa), and phospho-NF-κB (ser536)
(∼65 kDa) was quantified by densitometric scanning of
the X-ray films with GS-700 Imaging Densitometer (GS-
700, Bio-Rad Laboratories, Milan, Italy) and a computer
program (Molecular Analyst, IBM), and standardized for
densitometric analysis to β-actin and lamin B1 protein levels.
2.11. Materials. Unless otherwise stated, all compounds were
obtained from Sigma-Aldrich Company Ltd. (Poole, Dorset,
UK). AM was obtained from Bachem (St. Helens, UK).
All other chemicals were of the highest commercial grade
available. All stock solutions were prepared in nonpyrogenic
saline (0.9% NaCl; Baxter, Italy, UK).
2.12. Statistical Evaluation. All values in the figures and text
are expressed as mean ± standard error (s.e.m.) of the mean
of n observations. For the in vivo studies n represents the
number of animals studied. In the experiments involving
histology or immunohistochemistry, the figures shown are
representative of at least three experiments (histological or
immunohistochemistry coloration) performed on diﬀerent
experimental days on the tissue sections collected from all the
animals in each group. The results were analyzed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s post
hoc test for multiple comparisons and assessed with two-way
anova for repeated measures and followed by Student’s t-
test. A P value of less than 0.05 was considered statistically
significant.
3. Results
3.1. Eﬀects of AM on CAR-Induced Pleurisy. When compared
to lung sections taken from saline-treated animals (sham
group, Figure 1(a), see densitometry analysis in Figure 1(d)),
histological examination of lung sections taken from mice
treated with CAR revealed significant tissue damage and
edema (Figure 1(b), see histological score in Figure 1(d)),
as well as infiltration of neutrophils (PMNs) within the
tissues (Figure 1(b)). However, AM reduced in a dose-
dependent manner the degree of lung injury (Figure 1(c), see
histological score in Figure 1(d)).
The pleural infiltration with PMN appeared to correlate
with an influx of leukocytes into the lung tissue, thus we
investigated the eﬀect of AM on neutrophil infiltration by
measurement of MPO activity; This enzyme activity was
significantly elevated at 4 h after CAR administration in
vehicle-treated mice (Figure 1(e)). Treatment with AM sig-
nificantly attenuated in a dose-dependentmanner neutrophil
infiltration into the lung tissue (Figure 1(e)).
3.2. Eﬀects of AM on the Expression of Adhesion Molecules
(ICAM-1, P-Selectin). No positive staining for ICAM-1 and
P-selectin was found in lung tissue sections from saline-
treated mice (Figures 2(a) and 2(d), resp.). At 4 h after
CAR injection, the ICAM-1 staining intensity increased
in the vascular endothelium (Figure 2(b)). In the same
line, lung tissue sections obtained from CAR-treated mice
showed positive staining for P-selectin localized in the vessels
(Figure 2(e)). No positive staining for ICAM-1 or P-selectin
was observed in the lungs of CAR-treated mice pretreated
with AM (Figures 2(c) and 2(f), resp.). Western blotting
study confirmed results from immunohistochemical analy-
sis, showing a significant increase in ICAM-1 (Figure 2(g)
see densitometry Figure 2(g1)) and P-selectin (Figure 2(h)
see densitometry Figure 2(h1)) quantification in lungs taken
from mice subjected to CAR-induced pleurisy. However, in
AM-treated mice a lower quantification of these proteins
could be detected (Figures 2(g) and 2(h) see densitometry
Figures 2(g1) and 2(h1)).
3.3. Eﬀects of AM on iNOS Expression and Nitrite-Nitrate
Concentration. No positive staining for iNOS was observed
in the lung tissues obtained from the sham group (Fig-
ure 3(a)). Immunohistochemical analysis of lung sections
obtained from CAR-treated mice revealed positive staining
for iNOS (Figure 3(b)). AM treatment (200 ng/kg) sig-
nificantly attenuated this protein expression (Figure 3(c)).
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Figure 1: Eﬀect of adrenomedullin (AM) on histological alterations and on PMN infiltration in the lung. Lung sections taken from CAR-
treated mice treated with vehicle demonstrated edema, tissue injury (b, d), as well as infiltration of the tissue with neutrophils (b). CAR-
treated animals treated with AM (c) demonstrated reduced lung injury and neutrophil infiltration in a dose-dependent manner. Section
from sham animals showed the normal architecture of the lung tissue (a). The histological score (d) was made by an independent observer.
MPO activity, index of PMN infiltration, was significantly elevated at 4 h after CAR administration in vehicle-treated mice (e), if compared
with sham mice (e). AM significantly reduced MPO activity in the lung in a dose-dependent manner (e). The figure is representative of
at least 3 experiments performed on diﬀerent experimental days. Data are expressed as mean ± s.e.m. from n = 10 mice for each group.
∗P < 0.01 versus sham group. ◦P < 0.01 versus CAR.
Western blotting study confirmed results from immunohis-
tochemical analysis, showing a significant increase in iNOS
quantification in lungs taken from mice subjected to CAR-
induced pleurisy. However, in AM-treated mice a lower
quantification of this inducible protein could be detected
(Figure 3(e), see densitometry analysis in Figure 3(e1)).
NO levels were also significantly increased in the exudates
obtained from mice administered CAR in comparison with
those from sham animals (Figure 3(d)). By contrast, treat-
ment of mice with AM significantly reduced NO levels
(Figure 3(d)).
3.4. Eﬀects of AM on CAR-Induced Nitrotyrosine Formation,
Lipid Peroxidation, and PARP Activation. Immunohisto-
chemical analysis of lung sections obtained from mice
treated with CAR revealed positive staining for nitrotyrosine
(Figure 4(b) see densitometry Figure 4(d)). In contrast,
no positive staining for nitrotyrosine was found in the
lungs of CAR-treated mice, which had been treated with
AM (200 ng/kg) (Figure 4(c) see densitometry Figure 4(d)).
At the same time point (4 h after CAR administration),
lung tissue sections were taken in order to determine the
immunohistological staining for poly ADP-ribosylated pro-
teins (an indicator of PARP activation). A positive staining
for the PARP (Figure 4(f) see densitometry Figure 4(d)) was
found primarily localized in the inflammatory cells present
in the lung tissue from CAR mice. AM reduced the degree of
PARP activation (Figure 4(g) see densitometry Figure 4(d)).
Note that there was no staining for either nitrotyrosine (Fig-
ure 4(a) see densitometry Figure 4(d)) or PAR (Figure 4(e)
see densitometry Figure 4(d)) in lung tissues obtained from
the sham group of mice. In addition, at 4 hours after the
pleurisy was induced, MDA levels were also measured in
the lungs as an indicator of lipid peroxidation. As shown
in Figure 4(h), MDA levels were significantly increased
in the lungs of CAR-treated mice. Lipid peroxidation was
significantly attenuated by the intraperitoneal injection of
AM (Figure 4(h)).
3.5. Eﬀects of AM on the Release and Expression of Proin-
flammatory Cytokines Induced by CAR. When compared to
sham animals, injection of CAR resulted in an increase in the
levels of TNF-α and IL-1β in the pleural exudates (Figures
5(d) and 5(h), resp.). The release of these proinflammatory
cytokines was significantly attenuated by treatment with AM
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Figure 2: Eﬀect of adrenomedullin (AM) on the immunohistochemical localization of ICAM-1 and P-selectin. No positive staining for
ICAM-1 was observed in lung sections taken from sham mice treated with AM (a). Lung sections taken from CAR-treated mice showed
intense positive staining for ICAM-1 along the vessels (b). The degree of positive staining for ICAM-1 was markedly reduced in lung sections
obtained from mice treated with AM (c). No positive staining for P-selectin was observed in lung sections taken from sham mice (d).
Lung sections taken from CAR-treated mice treated with vehicle showed intense positive staining for P-selectin along the vessels (e). The
degree of positive staining for P-selectin was markedly reduced in tissue sections obtained from mice treated with AM (f). The figure is
representative of at least three experiments performed on diﬀerent experimental days. A significant increase in ICAM (g, g1) and P-selectin
(h, h1) quantification, assayed by western blot analysis, was detected in lungs obtained from mice subjected to CAR-induced pleurisy, if
compared with lung from sham mice (g, g1 and h, h1). Treatment with AM significantly attenuated these proteins quantification in the lung
tissues (g, g1 and h, h1). A representative blot of lysates obtained from 5 animals per group is shown and densitometry analysis of all animals
is reported. The results in panel (g1) and (h1) are expressed as mean ± s.e.m. from n = 5/6 lung tissues for each group. ∗P < 0.01 versus
sham group. ◦P < 0.01 versus CAR.
(Figures 5(d) and 5(h), resp.). Therefore, we also evalu-
ate the TNF-α and IL-1β expression in the lung tissues
by immunohistochemical detection. Tissue sections obtained
from vehicle-treated animals at 4 h after CAR injection
demonstrate positive staining for TNF-α mainly localized in
the infiltrated inflammatory cells, pneumocytes as well as
in vascular wall (Figure 5(b)). In contrast, no staining for
TNF-α was found in the lungs of CAR-treated mice that had
been also treated with AM (Figure 5(c)). Similarly, positive
staining for IL-1β, mainly, localized in the infiltrated inflam-
matory cells, was observed in lung tissue sections obtained
from vehicle-treated animals (Figure 5(f)). AM treatment
reduced the degree of IL-1β expression (Figure 5(g)). Please
note that there was no staining for either TNF-α (Figure 5(a))
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Figure 3: Eﬀect of adrenomedullin (AM) on iNOS expression and NO formation. Lung sections taken from CAR-treated mice treated with
vehicle showed positive staining for iNOS, localized mainly in inflammatory cells (b). The degree of positive staining for iNOS was markedly
reduced in tissue sections obtained from mice treated with AM (c). Lung sections taken from sham mice showed no staining for iNOS
(a). The figure is representative of at least 3 experiments performed on diﬀerent experimental days. A significant increase in iNOS (e, e1)
quantification, assayed by Western blot analysis, was detected in lungs obtained from mice subjected to CAR-induced pleurisy, if compared
with lung from sham mice (e, e1). Treatment with AM significantly attenuated this protein quantification in the lung tissues (e, e1). A
representative blot of lysates obtained from 5 animals per group is shown and densitometry analysis of all animals is reported. The results in
panel (e1) are expressed as mean ± s.e.m. from n = 5/6 lung tissues for each group. ∗P < 0.01 versus sham group. ◦P < 0.01 versus CAR.
Nitrite and nitrate levels, stable NO metabolites, were significantly increased in the pleural exudates at 4 h after CAR (CAR) administration
(d). AM significantly reduced the CAR-induced elevation of nitrite and nitrate in the exudates (d). Data are expressed as mean± s.e.m. from
n = 10 mice for each group. ∗P < 0.01 versus sham group. ◦P < 0.01 versus CAR.
or IL-1β (Figure 5(e)) in lung tissues obtained from the
sham group ofmice. To further characterize the carrageenan-
induced acute lung inflammation in AM-treated mice, the
anti-inflammatory cytokine IL-10 were measured in the lung
exudates. In CAR-treated mice however, significant decreases
(P < 0.01) in the levels of IL-10, in comparison to values
obtained in AM-treated mice, were detected (Figure 5(i)).
3.6. Eﬀect of AM on IκB-α Degradation NF-κB p65 Acti-
vation and IKK-α, PKA, and Phospho-NF-κB (Ser536). We
evaluated the quantification of IκB-α and nuclear NF-κB
p65 by western blot analysis to investigate the cellular
mechanisms whereby treatment with AM attenuates the
development of acute lung injury. Basal levels of IκB-
α was detected in lung samples from sham-treated ani-
mals, whereas IκB-α levels were substantially reduced in
lung tissues obtained from vehicle-treated animals at 4 h
after CAR injection (Figure 6(a), see densitometry analysis
Figure 6(a1)). AM (200 ng/kg) treatment prevented CAR-
induced IκB-α degradation (Figure 6(a), see densitometry
analysis in Figure 6(a1)). Moreover, NF-κB p65 levels in
the lung nuclear fractions were also significantly increased
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Figure 4: Eﬀect of adrenomedullin (AM) on nitrotyrosine formation, lipid peroxidation, and PARP activation. No staining for nitrotyrosine
is present in lung section from sham mice (a). Lung sections taken from CAR-treated mice treated with vehicle showed positive staining
for nitrotyrosine, localized mainly in inflammatory cells (b). There was a marked reduction in the immunostaining for nitrotyrosine in the
lungs of CAR-treated mice treated with AM (c). Malondialdehyde (MDA) levels, an index of lipid peroxidation, were significantly increased
in lung tissues 4 h after CAR administration (h), if compared with lung from sham mice (h). AM significantly reduced the CAR-induced
elevation of MDA tissue levels (h). Lung sections taken from CAR-treated mice showed positive staining for PAR (f). There was a marked
reduction in the immunostaining for PAR in the lungs of CAR-treated mice treated with AM (g). Lung section from sham mice showed
no staining for PAR (e). Densitometry analysis of immunocytochemistry photographs (n = 5 photos from each sample collected from all
mice in each experimental group) for nitrotyrosine and PAR from lung tissues was assessed (d). The assay was carried out by using Optilab
Graftek software on a Macintosh personal computer (CPU G3-266). Data are expressed as % of total tissue area. The figure is representative
of at least 3 experiments performed on diﬀerent experimental days. Data are expressed as mean ± s.e.m. from n = 10 mice for each group.
∗P < 0.01 versus sham group. ◦P < 0.01 versus CAR.
at 4 h after CAR injection compared to the sham-treated
mice (Figure 6(b), see densitometry analysis in Figure 6(b1)).
AM significantly reduced the levels of NF-κB p65, as shown
in Figure 6(b) (see densitometry analysis in Figure 6(b1)).
To confirm the nuclear translocation of active NFkB we
also evaluated the quantification of active IKK complex,
in particular of IKK alpha and phospho-NF-κB (ser536).
As shown in Figure 6(e), AM significantly reduced the
levels of IKK-α (see densitometry analysis in Figure 6(e1)).
A significant increase in the phosphorylation of Ser536
was observed in CAR-treated mice (Figure 6(c), see den-
sitometry analysis Figure 6(c1)). The treatment with AM
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Figure 5: Eﬀect of adrenomedullin (AM) on proinflammatory cytokine expression and release. Lung sections taken from CAR-treated mice
showed positive staining for TNF-α and IL-1β (b and f, resp.). There was a marked reduction in the immunostaining for TNF-α and IL-1β
in the lungs from CAR-treated mice treated with AM (c and g, resp.). No staining for either TNF-α (a) or IL-1β (e) in lung tissues obtained
from the sham group was detected. The figure is representative of at least 3 experiments performed on diﬀerent experimental days. Moreover,
pleural injection of CAR caused an increase in exudate levels of TNF-α (d) and IL-1β (h). AM significantly reduced TNF-α and Il-1b levels
(d and h, resp.). Finally IL-10 were measured in the lung exudates. In CAR-treated mice, however, significant decreases (P < 0.01) in the
levels of IL-10, in comparison to values obtained inAM-treated mice, were detected (i). Data are means ± s.e.m. of 10 mice for each group.
∗P < 0.01 versus sham group. ◦P < 0.01 versus CAR.
resulted in a significant decrease of the phosphorylation
of p65 on Ser536 (Figure 6(c), see densitometry analysis
Figure 6(c1)). In addition to explaining the AM interactions,
we evaluated the quantification of activates protein kinase
A (PKA). Whereas PKA levels were substantially reduced
in lung tissues obtained from vehicle-treated animals at
4 h after CAR injection (Figure 6(d), see densitometry
analysis Figure 6(d1)). AM (200 ng/kg) treatment prevented
CAR-induced PKA decreases (Figure 6(d), see densitometry
analysis in Figure 6(d1)).
4. Discussion
Neuropeptides produced during an ongoing inflammatory
response have emerged as endogenous anti-inflammatory
agents that participate in processes leading to the resolution
of inflammation and maintenance of tolerance. In this line,
AM is a vasorelaxant neuropeptide that has shown to be
an endogenous immunomodulatory factor, with predomi-
nant anti-inflammatory activities in diﬀerent experimental
conditions. These findings suggest that this peptide could
be an interesting potential alternative for the treatment
of immunological disorders [26, 27]. Considering these
beneficial eﬀects of AM, the present study investigated the
extent to which the administration of the peptide would
protect the lung in amodel of CAR-induced acute lung injury
in mice. The intrapleural injection of the polysaccharide
CAR elicits an inflammatory response characterized by
accumulation of fluid and migration of leukocytes to the
site of the inflammation [1]. Analysis of our results revealed
the anti-inflammatory actions of this peptide in the exper-
imental model of pleurisy. Edema and lung tissue damage
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Figure 6: Eﬀect of adrenomedullin (AM) on IκB-α degradation, nuclear NF-κB p65 quantification, IKK-α, PKA, and phospho-NF-κB
(ser536). Basal level of IκB-α was detected in lung samples from sham-treated animals, whereas IκB-α levels were substantially reduced
in lung tissues obtained from vehicle-treated animals at 4 h after CAR injection (a, a1). AM treatment prevented CAR-induced IκB-α
degradation (a, a1). NF-κB p65 levels in the lung nuclear fractions were significantly increased at 4 h after CAR injection compared to
the sham-treated mice (b, b1). AM treatment significantly reduced the levels of NF-κB p65 (b, b1). AM significantly reduced the levels of
IKK alpha (e, e1) and the phosphorylation of p65 on Ser536 (c, c1). Whereas prevented CAR-induced PKA decreases (d, d1). A representative
blot of lysates obtained from 5 animals per group is shown and densitometry analysis of all animals is reported. The results in panel (a1, b1,
c1, d1 and e1) are expressed as mean ± s.e.m. from n = 5/6 lung tissues for each group. ∗P < 0.01 versus sham group. ◦P < 0.01 versus
CAR.
were attenuated when AM was administered i.p. at the
dose of 200 ng/kg. Moreover, this peptide caused significant
inhibitory eﬀects on neutrophil influx into the pleural cavity
4 hour after CAR administration, as assessed by the histo-
logical analysis and in the specific granulocyte enzyme MPO
activity study. These results are in line with previous papers
which demonstrated that AM exerts a significant protective
eﬀect in lung injury. In this way, Itoh et al. [11] showed that
infusion of AM ameliorated LPS-induced acute lung injury
in rats. Moreover, a recent study reported the beneficial eﬀect
of the peptide on ventilator-induced lung injury in mice, due
in part to the attenuation of the accumulation of leucocytes
in the lung [28]. The maintenance of leukocyte recruitment
during inflammation requires intercellular communication
between infiltrating leukocytes and the endothelium. These
events are mediated by the generation of early response
cytokines, for example, IL-1β and TNF-α, which act on
the endothelial cell receptors inducing NO and cytokines
production and cellular adhesion molecules expression in
neutrophils [29]. We have already demonstrated in previous
study that TNF-α and IL-1β appear to play a critical role
in the induction of inflammatory responses by initiating
cytokine and chemokine cascades [30–32]. Blocking of
either of these cytokines results in profound reductions in
neutrophil influx and in the intensity of lung injury [33].
In accordance with these findings, we observed that AM
attenuated the TNF-α and IL-1β production in the pleural
exudates as well as their expression in the lung tissues
from CAR-treated mice. Our results may be supported
by earlier in vivo studies which show that the peptide
reduced the levels of TNF-α in bronchoalveolar lavage fluid
from rats with LPS-induced acute lung injury [11] and
in a model of intestinal ischemia/reperfusion-induced lung
injury [20]. In regards to adhesion molecules study, the
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peptide reduced the upregulation of the expression of ICAM-
1 and P-selectin on endothelial cells. Altogether, these data
may explain the downregulation of neutrophil infiltration
induced by AM treatment in our model of CAR-induced
acute lung injury. iNOS-induced NO production has been
shown to have proinflammatory action and it has been
associated with the initiation and maintenance of diﬀerent
experimental and clinic pathologies including lung diseases;
its overproduction leads to oxidative stress that may cause
cell death and tissue damage that characterize a number of
these pathologies [34, 35]. Our findings demonstrate that
AM significantly reduced the iNOS enzyme expression in
the lung tissues as well as the production of the stable
metabolites of NO in the exudates from CAR-instilled
mice. These data are in agreement with previous studies
reporting that this peptide inhibited NO production in both
experimental colitis [19] and LPS-activated macrophages
[17].
Activated neutrophils are reported to be one of the
main sources of ROS and RNS, which have been shown
to contribute to the pathogenesis of various inflammatory
lung injuries and other diseases. Along these lines, they
can initiate lipid peroxidation that results in both DNA
damage and destruction of the cell membranes involving
polyunsaturated fatty acids, which are extremely sensitive to
oxidation [36]. In the present study, we indicated that AM
treatment prevented the formation of MDA that is consid-
ered a good indicator of lipid peroxidation, which reflects
reduced oxidative stress. On the other hand, increased
production of NO combined with the production of ROS
contributes to the formation of highly reactive products such
as peroxynitrite. The formation of nitrotyrosine is a marker
for the detection of the generation of peroxynitrite and
other stress nitrosative derivatives [37]. Our results reveal
that the peptide attenuated the increase of nitrotyrosine
formation caused by CAR. We propose that this reduction of
nitrosative stress by AM may be attributed to the inhibition
of iNOS expression, and the subsequent formation of NO.
In addition, O2
−, a reactive oxygen species, and peroxynitrite
generated during lung injury trigger other cytotoxic eﬀects,
including DNA damage. They produce strand breakage of
DNA, inducing activation of the nuclear protein PARP. Once
activated, it catalyzes the cleavage of nicotinamide adenine
dinucleotide (NAD+) into nicotinamide and ADP-ribose
and then uses the latter to synthesize polymers of ADP-
ribose in DNA repair. However, under conditions of severe
DNA injury, overactivation of PARP severely depletes the
intracellular stores of NAD+, which aﬀects mitochondrial
respiration and cell energetic balance, ultimately leading to
cell death by necrosis [38]. In studies of acute lung injury
by various causes, PARP was shown to play a pivotal role
in the pathogenesis of the injury and PARP inhibitors have
therapeutic eﬀects [39–41]. We demonstrate here that AM
attenuated the increase in PARP activity caused by CAR
instillation. Taken together, these findings report that AM
reduced production/expression of markers of nitrosative and
oxidative stress and thus DNA damage in lung tissue. Our
observations are consistent with previous papers reporting
the antioxidant properties of AM. Along these lines, Matsui
et al. [42] and Kim et al. [43] have shown a protective
eﬀect of AM against hypoxia-induced pulmonary vascular
remodelling and hypoxia/reoxygenation-induced cell death,
respectively, through the inhibition of ROS production,
which might provide an eﬀective therapeutic strategy.
How do adrenomedullin regulate such a wide range
of inflammatory and immunomodulatory mediators? The
cAMP-PKA pathway is the main intracellular signalling
pathway that is involved in most of the eﬀects exerted by
all of these neuropeptides, including the downregulation
of inflammatory mediators [44]. cAMP-inducing agents
have been found to be potent anti-inflammatory factors.
They act by downregulating the activation of the nuclear
factor-B (NF-B), a factor that is essential for the transcrip-
tional activation of most of the inflammatory cytokines,
chemokines and costimulatory factors. These neuropeptides,
through increased levels of intracellular cAMP, decrease
NF-B nuclear translocation, and DNA binding induced
by diﬀerent bacterial products and cytokines by inhibiting
the phosphorylation and subsequent degradation of the
inhibitor of NF-κB, IkB, which retains p65 (an essential
component of the NF-κB transactivating complex) in the
cytoplasm [44].
In this way, Pleguezuelos and Kapas [45] reported that
AM was capable of abolishing the NF-κB translocation in
stimulated keratinocytes. In accordance with these find-
ings, we demonstrate that AM administration significantly
decreased the degradation of IκB-α and the nuclear translo-
cation of p65 in lung tissues, 4 h after CAR administra-
tion. Combining these results, it can be reported that the
reduction of TNF-α and IL-1β production or expression
and iNOS expression by AM described in the present study
is most likely attributed to an inhibitory eﬀect in NF-κB
activation.
5. Conclusions
In summary, our studies led to the conclusion that AM has
potential anti-inflammatory actions in the development of
CAR-induced pleurisy, attenuating NF-κB activation, and the
expression of proinflammatory cytokines and iNOS enzyme.
These eﬀects may explain the decrease in neutrophil migra-
tion and nitrosative and oxidative stress during the course
of the inflammatory response. Taken together, the results of
the present study enhance our understanding of the role of
the peptide AM in the pathophysiology of the inflammation
and support its therapeutic potential for lung inflammatory
pathologies.
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